Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 4:10:932085.
doi: 10.3389/fped.2022.932085. eCollection 2022.

Adverse Events of DOACs in Children

Alessandra Bosch  1 , Manuela Albisetti  2   3
Affiliations
Review

Adverse Events of DOACs in Children

Alessandra Bosch et al. Front Pediatr. .

Abstract

Venous thromboembolism (VTE) has an increasing rate of significance in pediatric patients. The currently standardized anticoagulants (unfractionated heparin, low molecular weight heparin and vitamin K antagonists) and their dose regimens were not comprehensively trialed in pediatric patients. Recently, several direct oral anticoagulants (DOACs) have been studied in clinical trials in the pediatric population and further trials are ongoing. Dabigatran etexilate and rivaroxaban results show that these DOACs are safe and efficient in the treatment and secondary prevention of pediatric VTE. This review will focus on adverse events (AEs) between specific DOACs reported in the clinical trials in children and compare them to standard of care. This will assist clinicians in decision making of selecting the right anticoagulation for their pediatric patients.

Keywords: DOACs; adverse events; bleeding complication; children; pediatric; serious adverse drug events.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Raffini L, Huang YS, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007. Pediatrics. (2009) 124:1001–8. 10.1542/peds.2009-0768 - DOI - PubMed
    1. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood. (1992) 80:1998–2005. 10.1182/blood.V80.8.1998.1998 - DOI - PubMed
    1. Bosch A, Albisetti M. Management of venous thromboembolism in children: current recommendations and therapeutic options. Ther Clin Risk Manag. (2020) 16:673–9. 10.2147/TCRM.S218622 - DOI - PMC - PubMed
    1. Male C, Lensing AWA, Palumbo JS, Kumar R, Nurmeev I, Hege K, et al. . Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. (2020) 7:e18–27. 10.1016/S2352-3026(19)30219-4 - DOI - PubMed
    1. Halton J, Brandão LR, Luciani M, Bomgaars L, Chalmers E, Mitchell LG, et al. . Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematol. (2021) 8:e22–33. 10.1016/S2352-3026(20)30368-9 - DOI - PubMed

LinkOut - more resources